Loxicodegol

Loxicodegol (also known as NKTR-181) is a novel opioid analgesic that was developed by Nektar Therapeutics for the management of chronic pain. It is a mu-opioid receptor agonist that is structurally related to oxycodone.

Pharmacology

Loxicodegol is a full agonist at the mu-opioid receptor. It is designed to have a slow rate of entry into the brain to reduce the euphoria and addiction potential associated with rapid-onset opioids.

Development and Approval

Loxicodegol was developed by Nektar Therapeutics. In March 2019, the U.S. Food and Drug Administration (FDA) did not approve the New Drug Application (NDA) for loxicodegol. The FDA stated that it was unable to approve the NDA in its present form and provided recommendations for additional data needed for approval.

Clinical Trials

Loxicodegol has undergone Phase 3 clinical trials for the management of chronic low back pain in opioid-naive patients. The results of the trials showed that loxicodegol was associated with less drug liking and less withdrawal than oxycodone.

See Also

• Opioid
• Chronic pain
• Nektar Therapeutics
• U.S. Food and Drug Administration

Loxicodegol Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski